DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs

Biochemical Pharmacology

Volumn 83, Issue 7, 2012, Pages 858-865

  Charlet, Jessica ^a   Schnekenburger, Michael ^b   Brown, Keith W ^a   Diederich, Marc ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

5 Aza 2 deoxycytidine; Chemotherapeutic drugs; DNA methylation; MYCN; Neuroblastoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DEMETHYLATION; DNA DETERMINATION; DNA METABOLISM; DNA METHYLATION; DRUG METABOLISM; DRUG UPTAKE; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROMORPHOLOGY; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIGENESIS, GENETIC; HUMANS; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84857365823     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.01.009     Document Type: Article

References (42)

1. J.M. Maris, M.D. Hogarty, R. Bagatell, and S.L. Cohn Neuroblastoma Lancet 369 2007 2106 2120
2. G.M. Brodeur Neuroblastoma: biological insights into a clinical enigma Nat Rev Cancer 3 2003 203 216
3. M. Schwab, K. Alitalo, K.H. Klempnauer, H.E. Varmus, J.M. Bishop, and F. Gilbert Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour Nature 305 1983 245 248
4. M.M. van Noesel, and R. Versteeg Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre' Gene 325 2004 1 15
5. V. van Limpt, A. Chan, A. Schramm, A. Eggert, and R. Versteeg Phox2B mutations and the delta-notch pathway in neuroblastoma Cancer Lett 228 2005 59 63
6. M. Holzel, S. Huang, J. Koster, I. Ora, A. Lakeman, and H. Caron NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome Cell 142 2010 218 229
7. D.A. Tweddle, A.D.J. Pearson, M. Haber, M.D. Norris, C. Xue, and C. Flemming The p53 pathway and its inactivation in neuroblastoma Cancer Lett 197 2003 93 98
8. Y.P. Mosse, M. Laudenslager, L. Longo, K.A. Cole, A. Wood, and E.F. Attiyeh Identification of ALK as a major familial neuroblastoma predisposition gene Nature 455 2008 930 935
9. H. Caren, F. Abel, P. Kogner, and T. Martinsson High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours Biochem J 416 2008 153 159
10. P. Lazcoz, J. Munoz, M. Nistal, A. Pestana, I. Encio, and J.S. Castresana Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma BMC Cancer 6 2006 254
11. Q. Yang, C.M. Kiernan, Y. Tian, H.R. Salwen, A. Chlenski, and B.A. Brumback Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome Clin Cancer Res 13 2007 3191 3197
12. Q. Yang, P. Zage, D. Kagan, Y. Tian, R. Seshadri, and H.R. Salwen Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma Clin Cancer Res 10 2004 8493 8500
13. J. Hoebeeck, E. Michels, F. Pattyn, V. Combaret, J. Vermeulen, and N. Yigit Aberrant methylation of candidate tumor suppressor genes in neuroblastoma Cancer Lett 273 2009 336 346
14. M. Alaminos, V. Davalos, N.K. Cheung, W.L. Gerald, and M. Esteller Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma J Natl Cancer Inst 96 2004 1208 1219
15. B. Banelli, I. Gelvi, A. Di Vinci, P. Scaruffi, I. Casciano, and G. Allemanni Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors Oncogene 24 2005 5619 5628
16. M. Abe, M. Ohira, A. Kaneda, Y. Yagi, S. Yamamoto, and Y. Kitano CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas Cancer Res 65 2005 828 834
17. P.G. Buckley, S. Das, K. Bryan, K.M. Watters, L. Alcock, and J. Koster Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions Int J Cancer 128 2011 2296 2305
18. A.R. Dallosso, A.L. Hancock, M. Szemes, K. Moorwood, L. Chilukamarri, and H.H. Tsai Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor PLoS Genet 5 2009 e1000745
19. T.R. Wilson, D.B. Longley, and P.G. Johnston Chemoresistance in solid tumours Ann Oncol 17 Suppl. 10 2006 x315 x324
20. J.M. Maris Recent advances in neuroblastoma N Engl J Med 362 2010 2202 2211
21. N. Keshelava, R.C. Seeger, and C.P. Reynolds Drug resistance in human neuroblastoma cell lines correlates with clinical therapy Eur J Cancer 33 1997 2002 2006
22. T. Teitz, T. Wei, M.B. Valentine, E.F. Vanin, J. Grenet, and V.A. Valentine Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN Nat Med 6 2000 529 535
23. G. Chen, Y. Wang, H. Huang, F. Lin, D. Wu, and A. Sun Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma Eur J Haematol 82 2009 176 183
24. M. Li, C. Balch, J.S. Montgomery, M. Jeong, J.H. Chung, and P. Yan Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer BMC Med Genomics 2 2009 34
25. S. Mirza, G. Sharma, P. Pandya, and R. Ralhan Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents Mol Cell Biochem 342 2010 101 109
26. D. Shang, Y. Liu, Q. Liu, F. Zhang, L. Feng, and W. Lv Synergy of 5-aza-2′-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines Cancer Lett 278 2009 82 87
27. M. Schnekenburger, C. Grandjenette, J. Ghelfi, T. Karius, B. Foliguet, and M. Dicato Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy Biochem Pharmacol 81 2011 364 378
28. C.J. Thiele Neuroblastoma cell lines J Hum Cell Cult 1 1998 21 53
29. C. Stresemann, and F. Lyko Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int J Cancer 123 2008 8 13
30. T. Qin, J. Jelinek, J. Si, J. Shu, and J.P. Issa Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines Blood 113 2009 659 667
31. K. Appleton, H.J. Mackay, I. Judson, J.A. Plumb, C. McCormick, and G. Strathdee Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors J Clin Oncol 25 2007 4603 4609
32. C.J. van Groeningen, A. Leyva, A.M. O'Brien, H.E. Gall, and H.M. Pinedo Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients Cancer Res 46 1986 4831 4836
33. F. Lyko, and R. Brown DNA methyltransferase inhibitors and the development of epigenetic cancer therapies J Natl Cancer Inst 97 2005 1498 1506
34. Y. Oki, E. Aoki, and J.P. Issa Decitabine - bedside to bench Crit Rev Oncol Hematol 61 2007 140 152
35. H. Donninger, M.D. Vos, and G.J. Clark The RASSF1A tumor suppressor J Cell Sci 120 2007 3163 3172
36. M.D. Vos, C.A. Ellis, A. Bell, M.J. Birrer, and G.J. Clark Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis J Biol Chem 275 2000 35669 35672
37. Y.Y. Qiu, B.L. Mirkin, and R.S. Dwivedi Differential expression of DNA-methyltransferases in drug resistant murine neuroblastoma cells Cancer Detect Prev 26 2002 444 453
38. Y.Y. Qiu, B.L. Mirkin, and R.S. Dwivedi Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells Cancer Detect Prev 29 2005 456 463
39. R.E. George, J.M. Lahti, P.C. Adamson, K. Zhu, D. Finkelstein, and A.M. Ingle Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a children's oncology group study Pediatr Blood Cancer 55 2010 629 638
40. M. Rodriguez-Paredes, and M. Esteller Cancer epigenetics reaches mainstream oncology Nat Med 17 2011 330 339
41. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, and S. Maheswaran A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
42. S.B. Baylin Resistance, epigenetics and the cancer ecosystem Nat Med 17 2011 288 289